Abstract P2-18-10: High risk of late in-breast tumour recurrence after BRCA1/2-associated breast cancer
Magnus Nilsson(Karolinska University Hospital), Niklas Loman(Lund University), Katharina Henriksson(Lund University), Åke Borg, Ulf Kristoffersson, Håkan Olsson(Nokia (Finland)), Linda Hartman(Lund University), Elsa Lanke(Lund University)
Cited by 0
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|646